BBIO - BridgeBio Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.93
+2.51 (+10.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close24.42
Open25.09
Bid0.00 x 800
Ask0.00 x 800
Day's Range23.19 - 27.20
52 Week Range14.23 - 48.36
Volume1,118,752
Avg. Volume920,196
Market Cap3.333B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.73
Earnings DateMar 01, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Why BridgeBio (BBIO) Stock Might be a Great Pick
      Zacks

      Why BridgeBio (BBIO) Stock Might be a Great Pick

      BridgeBio (BBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    • Is BridgeBio Pharma, Inc. (BBIO) A Good Stock To Buy?
      Insider Monkey

      Is BridgeBio Pharma, Inc. (BBIO) A Good Stock To Buy?

      We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

    • GlobeNewswire

      BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      PALO ALTO, Calif., April 03, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on.

    • GlobeNewswire

      BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

      BridgeBio Pharma, Inc. (BBIO) affiliate company QED Therapeutics announced today that patients have been dosed in separate Phase 3 and Phase 2 clinical trials of infigratinib in cancer indications. The Phase 3 PROOF 302 trial sponsored by QED is studying infigratinib for the adjuvant (post-surgery) treatment of invasive urothelial carcinoma.

    • GlobeNewswire

      BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

      BridgeBio Pharma, Inc. (BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering of $350 million aggregate principal amount of notes. In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of notes.

    • GlobeNewswire

      BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

      BridgeBio Pharma, Inc. (BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company expects to grant the initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of notes. The notes will be convertible at the option of holders, subject to certain conditions and during certain periods, into cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, with the form of consideration determined at the Company’s election.

    • GlobeNewswire

      BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress

      -Achieved multiple clinical and pre-clinical milestones across BridgeBio’s pipeline -Delivered pipeline expansion with addition of five new drug development and discovery.

    • GlobeNewswire

      BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors

      BridgeBio Pharma, Inc. (BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Ronald J. Daniels, president of Johns Hopkins University, to its board of directors, effective immediately. Serving as the 14th president of Johns Hopkins University since 2009, Daniels has championed interdisciplinary research and innovation initiatives, including the Johns Hopkins Precision Medicine Analytics Platform (PMAP), the Bloomberg-Kimmel Institute for Cancer Immunotherapy, and the recently announced partnership among the Johns Hopkins University School of Medicine, Bloomberg Philanthropies, and The New York Stem Cell Foundation Research Institute.

    • GlobeNewswire

      BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

      PALO ALTO, Calif., Feb. 21, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are.

    • GlobeNewswire

      BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

      BridgeBio Pharma, Inc. (BBIO) today disclosed four additional assets in its pipeline, expanding the number of disclosed programs to over 20 potential medicines. BridgeBio’s world-class team of experienced drug developers are advancing these therapies with the aim of delivering life-changing medicines to patients. BridgeBio founder and CEO Neil Kumar, Ph.D., will discuss these new assets and BridgeBio’s pipeline during a presentation at the 38th Annual J.P. Morgan Healthcare Conference today at 3 PM (PST) in San Francisco.

    • GlobeNewswire

      BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

      BridgeBio Pharma, Inc. (BBIO) today announced a collaboration agreement with Catalent to establish dedicated gene therapy development and manufacturing capacity at Catalent’s Paragon Gene Therapy clinical and commercial manufacturing center in Harmans, Maryland. The agreement is intended to support the clinical and commercial manufacturing needs for BridgeBio’s gene therapy product candidates for congenital adrenal hyperplasia, BBP-631, and Canavan disease, BBP-812.

    • GlobeNewswire

      BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

      BridgeBio Pharma, Inc. (BBIO) subsidiary QED Therapeutics announced today that it has secured both Fast Track Designation in adults with first-line advanced or metastatic cholangiocarcinoma and Orphan Drug Designation for infigratinib for treatment of cholangiocarcinoma. In addition, the company announced that enrollment is ongoing and patient dosing has started in the PROOF trial, a Phase 3 clinical trial evaluating oral infigratinib, an investigational drug, in adults for first-line treatment of advanced cholangiocarcinoma with FGFR2 (fibroblast growth factor receptor 2) gene fusions or translocations.

    • GlobeNewswire

      BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference

      PALO ALTO, Calif., Dec. 19, 2019 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday,.

    • GlobeNewswire

      BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

      BridgeBio Pharma, Inc. (BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD) Type A, and Medison Pharma Ltd., a leading commercial biotech partner that operates in Israel, Canada and Central and Eastern European countries, have entered into an exclusive license agreement under which Medison received rights from Origin to distribute, market, sell and otherwise commercialize Origin’s drug product known as fosdenopterin (BBP-870/ORGN001) in Israel.

    • The 5 top performing IPOs of 2019
      Yahoo Finance

      The 5 top performing IPOs of 2019

      These are the best performing IPOs of 2019.

    • GlobeNewswire

      BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

      BridgeBio Pharma, Inc. (BBIO) today announced it has appointed Jennifer Cook to its Board of Directors and will leverage her considerable expertise as a special advisor to the senior management team. “Jennifer is a seasoned leader in the biotech and pharmaceutical spaces, with decades of experience taking drugs from research to commercialization,” said Richard Scheller, Ph.D., chairman of research and development at BridgeBio.

    • BridgeBio Pharma, Inc. (BBIO): Are Hedge Funds Right About This Stock?
      Insider Monkey

      BridgeBio Pharma, Inc. (BBIO): Are Hedge Funds Right About This Stock?

      The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

    • Benzinga

      The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares

      The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

    • GlobeNewswire

      BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

      BridgeBio Pharma, Inc. (BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Eli Wallace, Ph.D., as its chief scientific officer in residence for oncology effective immediately. In this new role, Dr. Wallace will oversee BridgeBio’s ongoing discovery efforts in targeted oncology while driving the identification and adoption of new oncology programs. “Eli is a brilliant medicinal chemist with an outstanding record of accomplishment in drug development at Array BioPharma and Peloton Therapeutics,” said Frank McCormick, Ph.D., chairman of oncology at BridgeBio.

    • GlobeNewswire

      BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

      BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for fosdenopterin (BBP-870/ORGN001) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. Currently, there are no approved therapies that alter the course of MoCD Type A, which results in severe and irreversible neurological injury. Fosdenopterin, an investigative cPMP substrate replacement therapy, aims to reduce buildup of toxic sulfites and alleviate central nervous system symptoms in infants and children with MoCD Type A.